Gossamer Bio is a San Diego-based biopharmaceutical company focused on discovering, developing, and commercializing immunology-based therapeutics across autoimmune, allergy/inflammation, and immuno-oncology areas. The company announced a $230 million Series B preferred stock financing led by Hillhouse Capital. Proceeds will be used to continue rapid company growth, advance clinical trials for multiple early- and late-stage drug candidates, and pursue additional business-development opportunities. Existing investors ARCH Venture Partners and Omega Funds meaningfully participated alongside new investors. Leadership changes accompanied the financing: Sheila Gujrathi was named CEO and Co-Founder Faheem Hasnain became full-time Executive Chairman. The company emphasizes creating value at the individual-asset level and long-term sustainability. Gossamer Bio was founded by the former Receptos executive team to discover and develop novel, differentiated therapeutics across immunology, inflammation, fibrosis and oncology. The company plans to leverage an asset‑rich in‑licensing environment to build its pipeline of clinical and preclinical assets. Its lead program is an oral, once‑daily therapy in a Phase 2b/3 development plan targeting specific patient subgroups with potential for a pipeline within a product. Gossamer launched with $100 million in financing to rapidly ramp operations, progress clinical trials for early and late‑stage candidates, and further augment the pipeline. The company is based in San Diego and is assembling a management and board team with prior industry experience and investor representation. No operating metrics (revenue/users) were disclosed in the announcement.

Total raised

$330M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2018